ProCE Banner Activity

Podcast Pearls
Overcoming Acquired Resistance With Second-Generation TRK Inhibitors

Slideset Download
Podcast Episodes
Download this short summary slideset based on the content from a CCO podcast covering key data on second-generation TRK inhibitors that can overcome resistance to first-generation agents in patients with NTRK fusion–positive solid tumors.

Released: November 09, 2021

Expiration: November 08, 2022

No longer available for credit.

Share

Faculty

George D. Demetri

George D. Demetri, MD

Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director,
Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Alexander Drilon

Alexander Drilon, MD

Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Bayer Healthcare Pharma

Faculty Disclosure

Primary Author

George D. Demetri, MD

Professor of Medicine
Harvard Medical School
Harvard University
Co-Director, Ludwig Center at Harvard
Senior Vice President for Experimental Therapeutics
Director,
Sarcoma Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Alexander Drilon, MD

Chief, Early Drug Development
Attending, Thoracic
Memorial Sloan Kettering Cancer Center
New York, New York